Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI
Status:
NOT_YET_RECRUITING
Trial end date:
2029-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if reducing the duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (short treatment regimen, stopping aspirin at day 7) is as safe and efficient as the standard DAPT duration (standard treatment regimen) in elderly patients 65 years.
The main questions it aims to answer are:
Does the reduction of the duration of DAPT reduces rates of bleeding without increasing the risk of cardiovascular events? Researchers will compare a short treatment by DAPT (7 days, followed by single antiplatelet therapy) to a standard treatment duration by DAPT (3 to 12 months) after successful percutaneous coronary intervention with 1 drug-eluting stent.
Participants will:
* Take aspirin for 7 days in one group or 3 to 12 months in another group
* Be contacted by phone at 7 days, 14 days, 21 days, 30 days, 3 months, 6 months and 12 months after hospital discharge
* Keep a diary of any bleeding or cardiovascular events occurring during the study period